Salvage surgery after combination immunotherapy for initially unresectable or metastastic hepatocellular carcinoma: A retrospective clinical study

• DOI: 10.1016/j.cson.2023.100025
• Publication Date: 2023-10-14T15:32:37Z
• Authors: Jun-Shuai Xue; Hui Liu; Rui-Zhe Li; Si-Yu Tan; Yu-Chuan Yan; Zhao-Ru Dong; Jian-Guo Hong; En-Yu Liu; Qiang-Bo Zhang; Zhi-Qiang Chen; Dong-Xu Wang; Tao Li
• Keywords: Leukocytopenia

Combination immunotherapy has gradually become the mainstay of systematic therapy for advanced hepatocellular carcinoma (HCC), however, whether preoperative potential to reduce tumor activity, increase resection rate and improve prognosis remains unclear. This study aimed investigate efficacy safety combined immunotherapies patients with initially unresectable HCC. retrospective, real-world involved HCC receiving based on PD-1/L1 blockade before surgery. Tumor treatment responses, pathological manifestations in postoperative specimens overall survival (OS) were evaluated. Treatment related adverse events (AEs) assessed according National Cancer Institute Common Terminology Criteria Adverse Events (NCI CTCAE, version 4.0). The consecutively included 54 34 evaluated safety, efficacy, possibility subsequent radical Among these surgical resection, 57.1% (n=8) combination surgery achieved a partial response (PR). Pathological evaluation confirmed that 21.4% (n=3) complete 78.6% (n=11) PR. 28.6% (4/14) encountered grade 3 or 4 AEs. main AEs fatigue (n=11; 78.6%), leukocytopenia (n=8; 57.1%) aspartate aminotransferase (AST) elevation (n=6; 42.9%). After immunotherapy, should be comprehensively they meet criteria resection. Surgical following might effectively safely control progression could at least some